PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-204
EHA Library, Pier Luigi Zinzani,
303389
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND EFFICACY OF TAK-079 IN PATIENTS WITH ITP
EHA Library, Jason Homsy,
298362
O2.8 LONG-TERM FOLLOW-UP OF A PHASE 1, FIRST-IN-HUMAN OPEN-LABEL STUDY OF LCAR-B38M, A STRUCTURALLY DIFFERENTIATED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING B-CELL MATURATION ANTIGEN (BCMA), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, J Liu,
290400